Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference, 4th edition, 372 pages

+ the daily Top 10


  Ovarian Neoplasms

  Free Subscription


03.08.2020

2 Am J Surg Pathol
1 BMC Cancer
1 Clin Cancer Res
6 Gynecol Oncol
1 Int J Oncol
3 Oncol Rep
2 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Am J Surg Pathol

  1. LESKELA S, Romero I, Cristobal E, Perez-Mies B, et al
    Mismatch Repair Deficiency in Ovarian Carcinoma: Frequency, Causes, and Consequences.
    Am J Surg Pathol. 2020;44:649-656.
    PubMed         Abstract available

  2. XING D, Zhong M, Ye F, O'Malley MT, et al
    Ovarian Intermediate Trophoblastic Tumors: Genotyping Defines a Distinct Category of Nongestational Tumors of Germ Cell Type.
    Am J Surg Pathol. 2019 Nov 1. doi: 10.1097/PAS.0000000000001402.
    PubMed         Abstract available


    BMC Cancer

  3. GOBEL A, Zinna VM, Dell'Endice S, Jaschke N, et al
    Anti-tumor effects of mevalonate pathway inhibition in ovarian cancer.
    BMC Cancer. 2020;20:703.
    PubMed         Abstract available


    Clin Cancer Res

  4. MORONEY JW, Powderly J, Lieu CH, Bendell JC, et al
    Safety and Clinical Activity of Atezolizumab Plus Bevacizumab in Patients with Ovarian Cancer: A Phase Ib Study.
    Clin Cancer Res. 2020 Jul 28. pii: 1078-0432.CCR-20-0477.
    PubMed         Abstract available


    Gynecol Oncol

  5. LORUSSO D, Marchetti C, Conte C, Giudice E, et al
    Bevacizumab as maintenance treatment in BRCA mutated patients with advanced ovarian cancer: A large, retrospective, multicenter case-control study.
    Gynecol Oncol. 2020 Jul 20. pii: S0090-8258(20)33657.
    PubMed         Abstract available

  6. ANGELES MA, Rychlik A, Cabarrou B, Spagnolo E, et al
    A multivariate analysis of the prognostic impact of tumor burden, surgical timing and complexity after complete cytoreduction for advanced ovarian cancer.
    Gynecol Oncol. 2020 Jul 22. pii: S0090-8258(20)32321.
    PubMed         Abstract available

  7. FALCONER H, Joneborg U, Krawiec K, Palsdottir K, et al
    Ultra-radical upfront surgery does not improve survival in women with advanced epithelial ovarian cancer; a natural experiment in a complete population.
    Gynecol Oncol. 2020 Jul 22. pii: S0090-8258(20)32384.
    PubMed         Abstract available

  8. ROBELIN P, Tod M, Colomban O, Lachuer J, et al
    Comparative analysis of predictive values of the kinetics of 11 circulating miRNAs and of CA125 in ovarian cancer during first line treatment (a GINECO study).
    Gynecol Oncol. 2020 Jul 22. pii: S0090-8258(20)33656.
    PubMed         Abstract available

  9. SCHWARTZ GG, Tretli S, Klug MG, Robsahm TE, et al
    Women who develop ovarian cancer show an increase in serum calcium and a decrease in serum albumin. A longitudinal study in the Janus Serum Bank Cohort.
    Gynecol Oncol. 2020 Jul 25. pii: S0090-8258(20)32381.
    PubMed         Abstract available

  10. TEWARI KS, Sill MW, Coleman RL, Aghajanian C, et al
    Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group study.
    Gynecol Oncol. 2020 Jul 25. pii: S0090-8258(20)32390.
    PubMed         Abstract available


    Int J Oncol

  11. LIU L, Yuan L, Huang D, Han Q, et al
    miR126 regulates the progression of epithelial ovarian cancer in vitro and in vivo by targeting VEGFA.
    Int J Oncol. 2020;57:825-834.
    PubMed         Abstract available


    Oncol Rep

  12. LIU P, Zhong Y, Cao T, Sheng X, et al
    A frequent somatic mutation in the 3'UTR of GAPDH facilitates the development of ovarian cancer by creating a miR125b binding site.
    Oncol Rep. 2020;44:887-896.
    PubMed         Abstract available

  13. ZHOU S, Wang R, Xiao H
    Adipocytes induce the resistance of ovarian cancer to carboplatin through ANGPTL4.
    Oncol Rep. 2020;44:927-938.
    PubMed         Abstract available

  14. ZHANG R, Chen X, Fu S, Xu L, et al
    A small molecule STAT3 inhibitor, LLL12, enhances cisplatin and paclitaxelmediated inhibition of cell growth and migration in human ovarian cancer cells.
    Oncol Rep. 2020;44:1224-1232.
    PubMed         Abstract available


    PLoS One

  15. KELM NQ, Straughn AR, Kakar SS
    Withaferin A attenuates ovarian cancer-induced cardiac cachexia.
    PLoS One. 2020;15:e0236680.
    PubMed         Abstract available

  16. JOHNSON SC, Chakraborty S, Drosou A, Cunnea P, et al
    Inflammatory state of lymphatic vessels and miRNA profiles associated with relapse in ovarian cancer patients.
    PLoS One. 2020;15:e0230092.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: